Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00538785 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,236
- Enrollment target
NCT00538785 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 1,236 participants.
The verdict
NCT00538785, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,236 participants
- Enrollment target
Study Summary
The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.
Interventions
- BIOLOGICAL Palivizumab
- BIOLOGICAL Motavizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,236 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00538785
The ClinicalTrials.gov registry entry for NCT00538785 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Palivizumab is the first listed.
NCT00538785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00538785 about?
NCT00538785 is a clinical study titled "A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease". The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.
What is the current status of trial NCT00538785?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,236 participants. The study started on 2005-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00538785?
The interventions under investigation include: Palivizumab (BIOLOGICAL), Motavizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00538785?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.